21158 WEBCAST: New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment with Novel Therapeutics

In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients.

This activity can be accessed using the following URL: www.peerview.com/VVY

Target Audience

  • Hematologists-Oncologists
  • Medical Oncologists
  • BMT Specialists
  • BMT Nurse Specialists
  • Other Clinician Involved in the Management of GVHD

Learning Objectives

Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD
Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting
Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics
Additional information

Contact

Name: 
Sherry Fisher
Phone Number: 
+1 (414) 805-0687
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
02/23/2021
Course expires: 
02/22/2022
Cost:
$0.00

Support Statement
This activity is supported by educational grants from CSL Behring, Incyte Corporation, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

 

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chairs & Presenters
Corey Cutler, MD, MPH, FRCP(C)
Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey Cutler, MD, MPH, FRCP(C), has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Generon; Genzyme Corporation; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Omeros Corporation; and Syndax.

Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplantation Service
Associate Member
Memorial Sloan Kettering Cancer Center
New York, New York

CME Reviewer
Anita D’Souza, MD

Anita D’Souza, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

 

 

image

The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.